| Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) (NCT00705198) | Merck Sharp & Dohme LLC | 2006-09-01 |
| 131-I-TM-601 Study in Adults With Solid Tumors (NCT00379132) | TransMolecular | 2006-08-01 |
| The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) (NCT00392171) | Merck Sharp & Dohme LLC | 2006-06-09 |
| Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology (NCT00330109) | AHS Cancer Control Alberta | 2006-06-01 |
| Experience of Brain Tumor Caregivers (NCT00352820) | M.D. Anderson Cancer Center | 2006-04-01 |
| A Phase I Study of ECO-4601 in Patients With Advanced Cancer (NCT00338026) | Thallion Pharmaceuticals | 2006-02-01 |
| Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas (NCT00360828) | H. Lee Moffitt Cancer Center and Research Institute | 2006-02-01 |
| A Dose-Escalation Study in Participants With Recurrent Malignant Glioma (NCT01682187) | Eli Lilly and Company | 2005-12-15 |
| A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas (NCT00526812) | Biogen | 2005-11-30 |
| Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG) (NCT00137488) | AHS Cancer Control Alberta | 2005-11-01 |
| Enzastaurin to Treat Recurrent Brain Tumor (NCT00108056) | National Cancer Institute (NCI) | 2005-04-07 |
| Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors (NCT00108069) | National Cancer Institute (NCI) | 2005-04-01 |
| Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis (NCT00185848) | Sanjiv Sam Gambhir | 2005-04-01 |
| GW572016 to Treat Recurrent Malignant Brain Tumors (NCT00107003) | National Cancer Institute (NCI) | 2005-03-30 |
| Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide (NCT00250211) | AHS Cancer Control Alberta | 2005-03-01 |
| A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers (NCT00122239) | AHS Cancer Control Alberta | 2005-01-01 |
| Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy (NCT00214175) | University of Wisconsin, Madison | 2004-06-01 |
| Gliogene: Brain Tumor Linkage Study (NCT00418899) | M.D. Anderson Cancer Center | 2004-02-12 |
| Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents (NCT00147160) | Gustave Roussy, Cancer Campus, Grand Paris | 2003-10-01 |
| Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas (NCT00412542) | M.D. Anderson Cancer Center | 2003-10-01 |
| The Role of Gene Changes in Brain Tumor Formation and Growth (NCT00059020) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-04-01 |
| Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas (NCT00047879) | National Cancer Institute (NCI) | 2002-10-01 |
| Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. (NCT00040573) | TransMolecular | 2002-06-01 |
| Genetic Analysis of Brain Tumors (NCT00031538) | National Cancer Institute (NCI) | 2002-03-01 |
| Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma (NCT00213278) | The Hospital for Sick Children | 2002-01-01 |
| Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer (NCT00028158) | MediGene | 2001-12-01 |
| Study of Vioxx and Radiation Therapy for Brainstem Glioma (NCT00038389) | M.D. Anderson Cancer Center | 2001-10-01 |
| Prolonged Daily Temozolomide for Low-Grade Glioma (NCT00165360) | Dana-Farber Cancer Institute | 2001-09-01 |
| Natural History of Patients With Brain and Spinal Cord Tumors (NCT00009035) | National Cancer Institute (NCI) | 2001-01-22 |
| Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor (NCT00001148) | National Institute of Neurological Disorders and Stroke (NINDS) | 1999-10-01 |
| A Family Study of Adults With Glioma (NCT00339352) | National Institutes of Health Clinical Center (CC) | 1999-03-11 |
| A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy (NCT00001573) | National Cancer Institute (NCI) | 1997-03-01 |
| A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors (NCT00001502) | National Cancer Institute (NCI) | 1996-04-01 |
| Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma (NCT03722355) | Radiation Therapy Oncology Group | 1990-11-09 |
| The Etiology and Progression of Brain Tumors (NCT01811524) | Tampere University Hospital | 1983-09-01 |
| Evaluation of Factors in Human Brain Tumors (NCT00001171) | National Institute of Neurological Disorders and Stroke (NINDS) | 1979-07-01 |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas (NCT00080054) | Pharmacyclics LLC. | |
| Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas (NCT04617002) | Jazz Pharmaceuticals | |
| Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas (NCT03134131) | Jazz Pharmaceuticals | |
| Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas (NCT05392374) | Jazz Pharmaceuticals | |
| Vorasidenib Expanded Access Program (NCT05592743) | Servier | |